China NMPA accepts Akeso's sNDA penpulimab combination therapy for first-line treatment of hepatocellular carcinoma: Hong Kong Monday, November 25, 2024, 13:00 Hrs [IST] Akeso, In ...

Combination of radiation, chemotherapy and immunotherapy can shrink tumors and allow surgery, with much better survival rate.